US5541231A
(en)
*
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
GB9315856D0
(en)
*
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
US5616344A
(en)
*
|
1994-06-14 |
1997-04-01 |
Fuisz Technologies Ltd. |
Apparatus and process for strengthening low density compression dosage units and product therefrom
|
DE59804823D1
(de)
*
|
1997-09-25 |
2002-08-22 |
Bayer Ag |
Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
|
US6221917B1
(en)
|
1997-12-30 |
2001-04-24 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US5968553A
(en)
*
|
1997-12-30 |
1999-10-19 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
|
US7098206B2
(en)
*
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
*
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
EP1051163A2
(de)
*
|
1998-01-29 |
2000-11-15 |
Sepracor, Inc. |
Methoden und zusammenstellungen zur hilfe beim einstellen des rauchens und zur behandlung von schmerzen und anderen krankheiten durch verwendung von optisch reinem (-)-bupropion
|
EP1051164A1
(de)
|
1998-01-29 |
2000-11-15 |
Sepracor, Inc. |
Pharmazeutische anwendungen von reinem (+)-bupropion
|
US6110973A
(en)
*
|
1998-01-29 |
2000-08-29 |
Sepracor |
Methods for treating obesity and weight gain using optically pure (-)-bupropion
|
JP2002501890A
(ja)
*
|
1998-01-29 |
2002-01-22 |
セプラコア インコーポレーテッド |
光学的に純粋な(+)−ビュープロピオンの薬学的使用
|
US6150420A
(en)
*
|
1998-06-01 |
2000-11-21 |
Theramax, Inc. |
Method for enhanced brain delivery of bupropion
|
US6153223A
(en)
*
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
US6033686A
(en)
*
|
1998-10-30 |
2000-03-07 |
Pharma Pass Llc |
Controlled release tablet of bupropion hydrochloride
|
US6096341A
(en)
*
|
1998-10-30 |
2000-08-01 |
Pharma Pass Llc |
Delayed release tablet of bupropion hydrochloride
|
US6238697B1
(en)
*
|
1998-12-21 |
2001-05-29 |
Pharmalogix, Inc. |
Methods and formulations for making bupropion hydrochloride tablets using direct compression
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6855820B2
(en)
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6589553B2
(en)
*
|
2001-02-08 |
2003-07-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral dosage form
|
US6210716B1
(en)
*
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6337328B1
(en)
*
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6342496B1
(en)
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
USD430285S
(en)
*
|
1999-04-16 |
2000-08-29 |
Merck & Co., Inc. |
Tablet
|
US6280763B1
(en)
|
1999-05-10 |
2001-08-28 |
Pierce Management, Llc |
Apparatus and method for transdermal delivery of bupropion
|
EP1242057A2
(de)
*
|
1999-11-02 |
2002-09-25 |
DepoMed, Inc. |
Pharmakologische induzierung von verdauungsmodus zur verbesserten arzneistoffabreichung an die magen
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
CA2685214C
(en)
*
|
2001-02-08 |
2013-01-22 |
Andrx Pharmaceuticals, Inc. |
Improved controlled release oral dosage form
|
ITMI20011457A1
(it)
*
|
2001-07-09 |
2003-01-09 |
Valpharma Sa |
Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
|
US20030044462A1
(en)
*
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
EP2316468A1
(de)
|
2002-02-22 |
2011-05-04 |
Shire LLC |
Abgabesystem und Verfahren zum Schutz und zur Verabreichung von Dextroamphetamin
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
EP2301537A1
(de)
*
|
2002-05-17 |
2011-03-30 |
Duke University |
Zonisamid zur Behandlung von Fettleibigkeit
|
US7776314B2
(en)
|
2002-06-17 |
2010-08-17 |
Grunenthal Gmbh |
Abuse-proofed dosage system
|
AU2003284942A1
(en)
*
|
2002-10-30 |
2004-06-07 |
Pharmacia Corporation |
Oral extended release tablets and methods of making and using the same
|
US20040096497A1
(en)
*
|
2002-11-19 |
2004-05-20 |
Ponder Garratt W. |
Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
|
US6893660B2
(en)
*
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
US7375111B2
(en)
|
2003-04-29 |
2008-05-20 |
Orexigen Therapeutics, Inc. |
Compositions for affecting weight loss
|
DE102004032051A1
(de)
*
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
|
US8075872B2
(en)
*
|
2003-08-06 |
2011-12-13 |
Gruenenthal Gmbh |
Abuse-proofed dosage form
|
DE10361596A1
(de)
|
2003-12-24 |
2005-09-29 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
US20070048228A1
(en)
*
|
2003-08-06 |
2007-03-01 |
Elisabeth Arkenau-Maric |
Abuse-proofed dosage form
|
DE10336400A1
(de)
|
2003-08-06 |
2005-03-24 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte Darreichungsform
|
DE102005005446A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Bruchfeste Darreichungsformen mit retardierter Freisetzung
|
CN1819821B
(zh)
*
|
2003-08-08 |
2010-10-13 |
拜奥维尔实验室国际股份有限公司 |
盐酸安非他酮的改良释放片剂
|
US7713959B2
(en)
*
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
US20060160750A1
(en)
*
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
JP2007517901A
(ja)
|
2004-01-13 |
2007-07-05 |
デューク・ユニバーシティー |
体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
|
US20060100205A1
(en)
*
|
2004-04-21 |
2006-05-11 |
Eckard Weber |
Compositions for affecting weight loss
|
DE102004032049A1
(de)
|
2004-07-01 |
2006-01-19 |
Grünenthal GmbH |
Gegen Missbrauch gesicherte, orale Darreichungsform
|
US8586085B2
(en)
|
2004-11-08 |
2013-11-19 |
Biokey, Inc. |
Methods and formulations for making pharmaceutical compositions containing bupropion
|
US20060099262A1
(en)
*
|
2004-11-08 |
2006-05-11 |
Biokey, Inc. |
Methods and formulations for making controlled release oral dosage form
|
GB0425445D0
(en)
*
|
2004-11-18 |
2004-12-22 |
Smithkline Beecham Corp |
Novel compositions
|
KR100670798B1
(ko)
|
2004-12-17 |
2007-01-17 |
한국전자통신연구원 |
데이터베이스 캐시 시스템
|
DE102005005449A1
(de)
|
2005-02-04 |
2006-08-10 |
Grünenthal GmbH |
Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
|
EP2502621A1
(de)
*
|
2005-06-27 |
2012-09-26 |
Valeant International (Barbados) SRL |
Kristalline Formen von Bupropion HBr
|
ZA200804086B
(en)
*
|
2005-10-14 |
2009-07-29 |
Lundbeck & Co As H |
Stable pharmaceutical formulations containing escitalo-pram and bupropion
|
JP2009511606A
(ja)
*
|
2005-10-14 |
2009-03-19 |
ハー・ルンドベック・アクチエゼルスカベット |
エスシタロプラムおよびブプロピオンの低用量の併用を用いる中枢神経系障害の治療方法
|
EP2135603B1
(de)
|
2005-11-22 |
2013-01-02 |
Orexigen Therapeutics, Inc. |
Zusammensetzungen und Verfahren zur Erhöhung der Insulinsensitivität
|
PT1954241E
(pt)
*
|
2005-11-28 |
2012-06-01 |
Orexigen Therapeutics Inc |
Formulação de zonisamida de libertação sustentada
|
WO2007101224A2
(en)
*
|
2006-02-27 |
2007-09-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibitors of the unfolded protein response and methods for their use
|
US20090181098A1
(en)
|
2006-03-07 |
2009-07-16 |
Osteoscreen Ip, Llc |
Hmg-Co-a Reductase Inhibitor Enhancement of Bone and Cartilage
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
WO2008042480A2
(en)
|
2006-06-13 |
2008-04-10 |
The Board Of Trustees Of The Leland Stanford Junior University |
Epoxide inhibitors of cysteine proteases
|
US8703191B2
(en)
*
|
2006-07-25 |
2014-04-22 |
Intelgenx Corp. |
Controlled-release pharmaceutical tablets
|
US7674479B2
(en)
*
|
2006-07-25 |
2010-03-09 |
Intelgenx Corp. |
Sustained-release bupropion and bupropion/mecamylamine tablets
|
US20100008987A1
(en)
*
|
2006-08-21 |
2010-01-14 |
Pasula Basavaiah Chowdary |
Modified Release Pharmaceutical Composition of Bupropion Hydrochloride
|
TW200829235A
(en)
|
2006-11-09 |
2008-07-16 |
Orexigen Therapeutics Inc |
Methods for administering weight loss medications
|
KR20190042766A
(ko)
|
2006-11-09 |
2019-04-24 |
오렉시젠 세러퓨틱스 인크. |
신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
|
DE102007011485A1
(de)
|
2007-03-07 |
2008-09-11 |
Grünenthal GmbH |
Darreichungsform mit erschwertem Missbrauch
|
RU2009141168A
(ru)
|
2007-04-09 |
2011-05-20 |
Сепракор Инк. (Us) |
Способы и композиции, содержащие дезвенлафаксин или дулоксетин, для лечения расстройств дыхания во время сна
|
CA2691208A1
(en)
*
|
2007-06-18 |
2008-12-24 |
The General Hospital Corporation |
Combination therapy for depression
|
US20090162434A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Disphar International Bv |
Mesalazine tablet
|
JP5774853B2
(ja)
|
2008-01-25 |
2015-09-09 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
医薬投薬形
|
WO2009111031A2
(en)
|
2008-03-04 |
2009-09-11 |
Intra-Cellular Therapies, Inc. |
Methods of treating vasomotor symptoms
|
WO2009135680A1
(en)
|
2008-05-09 |
2009-11-12 |
Grünenthal GmbH |
Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step
|
EP2303025A4
(de)
|
2008-05-30 |
2012-07-04 |
Orexigen Therapeutics Inc |
Verfahren zur behandlung von eingeweidefettbeschwerden
|
TW201039815A
(en)
|
2009-04-13 |
2010-11-16 |
Resolvyx Pharmaceuticals Inc |
Compositions and methods for the treatment of inflammation
|
CA2765971C
(en)
*
|
2009-07-22 |
2017-08-22 |
Gruenenthal Gmbh |
Hot-melt extruded controlled release dosage form
|
AU2010275755B2
(en)
|
2009-07-22 |
2014-04-24 |
Grünenthal GmbH |
Oxidation-stabilized tamper-resistant dosage form
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
US20110136815A1
(en)
*
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
MX344303B
(es)
|
2010-01-11 |
2016-12-13 |
Orexigen Therapeutics Inc |
Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
|
ES2606227T3
(es)
|
2010-02-03 |
2017-03-23 |
Grünenthal GmbH |
Preparación de una composición farmacéutica en polvo mediante una extrusora
|
PL2611425T3
(pl)
|
2010-09-02 |
2014-09-30 |
Gruenenthal Gmbh |
Odporna na ingerencję postać dawki zawierająca polimer anionowy
|
EP2611426B1
(de)
|
2010-09-02 |
2014-06-25 |
Grünenthal GmbH |
Manipulationssichere darreichungsform mit einem anorganischen salz
|
CN103327972A
(zh)
|
2010-10-11 |
2013-09-25 |
里兰斯坦福初级大学理事会 |
取代的苯甲酰胺及其用途
|
ES2794006T3
(es)
|
2010-10-26 |
2020-11-17 |
Mars Inc |
Inhibidores de arginasa como agentes terapéuticos
|
PT2736495T
(pt)
|
2011-07-29 |
2017-11-30 |
Gruenenthal Gmbh |
Comprimido resistente à adulteração proporcionando libertação imediata de fármaco
|
HUE034710T2
(hu)
|
2011-07-29 |
2018-02-28 |
Gruenenthal Gmbh |
Visszaéléssel szemben ellenálló, azonnali hatóanyagfelszabadulást biztosító tabletta
|
KR102042290B1
(ko)
|
2011-11-21 |
2019-11-07 |
칼리테라 바이오사이언시즈, 인코포레이티드 |
글루타미나제의 헤테로사이클릭 억제제
|
WO2013127831A1
(en)
|
2012-02-28 |
2013-09-06 |
Grünenthal GmbH |
Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
|
SG10201509063SA
(en)
|
2012-04-12 |
2015-12-30 |
Univ Leland Stanford Junior |
Substituted benzamides and their uses
|
MX362357B
(es)
|
2012-04-18 |
2019-01-14 |
Gruenenthal Gmbh |
Forma de dosificacion farmaceutica resistente a la adulteracion y resistente a la liberacion inmediata de la dosis.
|
US10064945B2
(en)
|
2012-05-11 |
2018-09-04 |
Gruenenthal Gmbh |
Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
|
EP4104824A1
(de)
|
2012-06-06 |
2022-12-21 |
Nalpropion Pharmaceuticals LLC |
Zusammensetzung zur verwendung in einem verfahren zur behandlung von übergewicht und fettleibigkeit bei patienten mit hohem kardiovaskulärem risiko
|
BR112015010955A2
(pt)
|
2012-11-16 |
2017-07-11 |
Calithera Biosciences Inc |
inibidores de glutaminase heterocíclica
|
ES2938225T3
(es)
|
2013-03-15 |
2023-04-05 |
Univ Leland Stanford Junior |
Compuestos de sondas basadas en la actividad, composiciones y métodos de uso
|
EP3003283A1
(de)
|
2013-05-29 |
2016-04-13 |
Grünenthal GmbH |
Manipulationssichere darreichungsform mit bimodalem freisetzungsprofil
|
EP3003279A1
(de)
|
2013-05-29 |
2016-04-13 |
Grünenthal GmbH |
Manipulationssichere darreichungsform mit einem oder mehreren partikeln
|
JP6449871B2
(ja)
|
2013-07-12 |
2019-01-09 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
エチレン−酢酸ビニルポリマーを含有する改変防止剤形
|
WO2015078891A1
(en)
|
2013-11-26 |
2015-06-04 |
Farmaceutici Formenti S.P.A. |
Preparation of a powdery pharmaceutical composition by means of cryo-milling
|
CN106572980A
(zh)
|
2014-05-12 |
2017-04-19 |
格吕伦塔尔有限公司 |
包含他喷他多的防篡改即释胶囊制剂
|
EP3148512A1
(de)
|
2014-05-26 |
2017-04-05 |
Grünenthal GmbH |
Gegen entsorgung von ethanolischer dosis gesicherte mehrfachpartikel
|
MX2016016364A
(es)
|
2014-06-13 |
2017-04-06 |
Calithera Biosciences Inc |
Terapia de combinacion con inhibidores de glutaminasa.
|
WO2016022969A1
(en)
|
2014-08-07 |
2016-02-11 |
Calithera Biosciences, Inc. |
Crystal forms of glutaminase inhibitors
|
ES2901418T3
(es)
|
2014-08-13 |
2022-03-22 |
Eolas Therapeutics Inc |
Difluoropirrolidinas como moduladores del receptor de orexina
|
WO2016070063A1
(en)
|
2014-10-31 |
2016-05-06 |
The Regents Of The University Of California |
Compositions and methods for treating hiv-associated cognitive dysfunction
|
CN107427477B
(zh)
|
2015-03-10 |
2021-11-26 |
奥瑞基尼探索技术有限公司 |
作为免疫调节剂的1,2,4-噁二唑和噻二唑化合物
|
EP3285745A1
(de)
|
2015-04-24 |
2018-02-28 |
Grünenthal GmbH |
Manipulationssichere darreichungsform mit sofortiger freisetzung und widerstand gegen lösungsmittelextraktion
|
AU2016281620B2
(en)
|
2015-06-23 |
2021-07-22 |
Calithera Biosciences, Inc. |
Compositions and methods for inhibiting arginase activity
|
KR102305932B1
(ko)
|
2015-06-29 |
2021-09-28 |
플로로놀 인코퍼레이티드 |
갈조류의 고체 약제학적 조성물
|
JP2018526414A
(ja)
|
2015-09-10 |
2018-09-13 |
グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング |
乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
|
GB2542881B
(en)
|
2015-10-02 |
2020-01-01 |
Carr Andrew |
Crystal forms of ß-nicotinamide mononucleotide
|
CA3000996A1
(en)
|
2015-10-05 |
2017-04-13 |
Calithera Biosciences, Inc. |
Combination therapy with glutaminase inhibitors and immuno-oncology agents
|
EP4011887A1
(de)
|
2015-10-30 |
2022-06-15 |
Calithera Biosciences, Inc. |
Zusammensetzungen und verfahren zur hemmung der arginaseaktivität
|
JP7019585B2
(ja)
|
2015-11-16 |
2022-02-15 |
アヴァロ セラピューティクス,インコーポレーテッド |
核酸プロドラッグ
|
KR20180107232A
(ko)
|
2016-02-12 |
2018-10-01 |
아스트라제네카 아베 |
오렉신 수용체 조정제로서의 할로-치환된 피페리딘
|
WO2017210565A1
(en)
|
2016-06-03 |
2017-12-07 |
Prisident And Fellows Of Harvard College |
Antifungal compounds
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
WO2018049094A1
(en)
|
2016-09-09 |
2018-03-15 |
The Regents Of The University Of California |
Estrogen receptor ligands, compositions and methods related thereto
|
EP3510040A4
(de)
|
2016-09-09 |
2020-06-03 |
Calithera Biosciences, Inc. |
Ektonukleotidasehemmer und verfahren zur verwendung davon
|
EP4275759A3
(de)
|
2016-09-26 |
2024-01-17 |
Dana-Farber Cancer Institute, Inc. |
Quinolin-derivate als chromobox (cbx) protein inhibitoren zur behandlung von krebs
|
BR112019006160A2
(pt)
|
2016-09-28 |
2019-06-18 |
Medicon Pharmaceuticals Inc |
composições e métodos para o tratamento das condições oftálmicas
|
DK3519050T3
(da)
|
2016-09-28 |
2023-07-24 |
Medicon Pharmaceuticals Inc |
Sammensætninger til behandling af oftalmiske sygdomme
|
EP3538111B1
(de)
|
2016-11-08 |
2022-01-19 |
Calithera Biosciences, Inc. |
Arginase-inhibitor-kombinationstherapien
|
MY197478A
(en)
|
2016-12-22 |
2023-06-19 |
Calithera Biosciences Inc |
Compositions and methods for inhibiting arginase activity
|
WO2018119476A1
(en)
|
2016-12-23 |
2018-06-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Activity-based probe compounds, compositions, and methods of use
|
BR112019014759A2
(pt)
|
2017-01-18 |
2020-03-03 |
Vanderbilt University |
Compostos heterocíclicos fundidos como inibidores seletivos de bmp
|
EA201991916A1
(ru)
|
2017-02-24 |
2020-01-21 |
Мерк Патент Гмбх |
1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ
|
EP3600270B1
(de)
|
2017-03-31 |
2023-06-14 |
Aurigene Oncology Limited |
Verbindungen und zusammensetzungen zur behandlung von hämatologischen störungen
|
WO2018209288A1
(en)
|
2017-05-12 |
2018-11-15 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded rna complexes and uses related thereto
|
WO2018223032A1
(en)
|
2017-06-02 |
2018-12-06 |
Stealth Biotherapeutics Corp. |
Crystalline salt forms of sbt-20
|
WO2019018539A1
(en)
|
2017-07-19 |
2019-01-24 |
California Institute Of Technology |
PROCESSES FOR PREPARING COMPOUNDS CONTAINING BIS-TETRAHYDROISOQUINOLINE
|
BR112020006669A2
(pt)
|
2017-10-11 |
2020-09-24 |
Aurigene Discovery Technologies Limited |
formas cristalinas de 1,2,4-oxadiazol 3-substituído
|
CN111225911B
(zh)
|
2017-10-31 |
2023-09-01 |
库里斯公司 |
用于治疗血液病的化合物和组合物
|
BR112020008537A2
(pt)
|
2017-11-03 |
2020-10-06 |
Aurigene Discovery Technologies Limited |
inibidores duplos de vias da tim-3 e da pd-1
|
JP7378395B2
(ja)
|
2017-11-06 |
2023-11-13 |
オーリジーン オンコロジー リミテッド |
免疫調節のためのコンジョイントセラピー
|
AR113995A1
(es)
|
2017-12-22 |
2020-07-08 |
Medimmune Ltd |
Moduladores de molécula pequeña del domino de btb de keap1
|
US10745400B2
(en)
|
2018-03-14 |
2020-08-18 |
Vanderbuilt University |
Inhibition of BMP signaling, compounds, compositions and uses thereof
|
WO2019200274A1
(en)
|
2018-04-12 |
2019-10-17 |
MatRx Therapeutics Corporation |
Compositions and methods for treating elastic fiber breakdown
|
WO2019217450A1
(en)
|
2018-05-08 |
2019-11-14 |
Rhode Island Hospital |
Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
|
WO2020006489A1
(en)
|
2018-06-29 |
2020-01-02 |
The Regents Of The University Of California |
New molecular tweezers against neurological disorders and viral infections
|
SG11202100429TA
(en)
|
2018-07-27 |
2021-02-25 |
California Inst Of Techn |
Cdk inhibitors and uses thereof
|
US20220218652A1
(en)
|
2018-09-05 |
2022-07-14 |
The General Hospital Corporation |
Methods of treating cytokine release syndrome
|
AU2019364631A1
(en)
|
2018-10-26 |
2021-06-03 |
Keros Therapeutics, Inc. |
Crystal forms of an ALK2 inhibitor
|
CR20210441A
(es)
|
2019-01-18 |
2022-03-11 |
Astrazeneca Ab |
Inhibidores de la pcsk9 y métodos de uso de los mismos
|
CN113631563A
(zh)
|
2019-01-25 |
2021-11-09 |
布朗大学 |
用于治疗、预防或逆转年龄相关炎症和疾病的组合物和方法
|
JP2022523510A
(ja)
|
2019-01-31 |
2022-04-25 |
エレクトロフィ,インコーポレイテッド |
粒子形成及び形態構造
|
MX2021011105A
(es)
|
2019-03-14 |
2021-10-22 |
Astrazeneca Ab |
Lanabecestat para la perdida de peso.
|
EP3978076A4
(de)
|
2019-06-03 |
2023-02-22 |
Irimajiri Therapeutics Inc. |
Zyklische amidverbindungen zur behandlung von tollwut und verfahren dafür
|
AU2020344675A1
(en)
|
2019-09-13 |
2022-03-31 |
Elektrofi, Inc. |
Compositions and methods for the delivery of therapeutic biologics for treatment of disease
|
JP2023500407A
(ja)
|
2019-11-12 |
2023-01-05 |
ジェンザイム・コーポレーション |
Cftr活性の欠損が介在する疾患及び状態を治療するための6員ヘテロアリールアミノスルホンアミド
|
WO2021113809A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
WO2021113806A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
CN114901290A
(zh)
|
2019-12-16 |
2022-08-12 |
蔚山科学技术院 |
抑制血管新生因子的化合物及其用途
|
US20230094393A1
(en)
|
2020-02-07 |
2023-03-30 |
Elektrofi, Inc. |
Peptide particles and methods of formation
|
WO2021168271A1
(en)
|
2020-02-19 |
2021-08-26 |
Elektrofi, Inc. |
Droplet formation and particle morphology
|
WO2021212019A1
(en)
|
2020-04-17 |
2021-10-21 |
Elektrofi, Inc. |
Methods of forming particles by continuous droplet formation and dehydration
|
WO2021263072A1
(en)
|
2020-06-25 |
2021-12-30 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating disease
|
CN111830151B
(zh)
*
|
2020-07-01 |
2021-05-04 |
迪沙药业集团有限公司 |
盐酸安非他酮组合物质量控制用系统适用性对照品
|
CA3191164A1
(en)
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
|
EP4192811A1
(de)
|
2020-08-10 |
2023-06-14 |
Dana-Farber Cancer Institute, Inc. |
Substituierte 3-amino-4-methylbenzolsulfonamide als kleinmolekülige inhibitoren der ubiquitinspezifischen protease 28
|
WO2022035806A1
(en)
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
|
US20230399304A1
(en)
|
2020-10-23 |
2023-12-14 |
Dana-Farber Cancer Institute, Inc. |
Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer
|
US20240058344A1
(en)
|
2020-12-18 |
2024-02-22 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
US11571481B2
(en)
|
2020-12-21 |
2023-02-07 |
Cornell University |
Peptide-linked drug delivery system
|
WO2022150574A1
(en)
|
2021-01-08 |
2022-07-14 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
IL311038A
(en)
|
2021-09-03 |
2024-04-01 |
Genzyme Corp |
Indole compounds and methods of use
|
WO2023034946A1
(en)
|
2021-09-03 |
2023-03-09 |
Genzyme Corporation |
Indole compounds and uses thereof in the treatement of cystic fibrosis
|
CA3231813A1
(en)
|
2021-10-01 |
2023-04-06 |
Sibao CHEN |
Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds
|
AU2022355108A1
(en)
|
2021-10-01 |
2024-04-04 |
Nuvalent, Inc. |
Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
|
WO2023187422A1
(en)
|
2022-03-31 |
2023-10-05 |
Revolo Biotherapeutics Limited |
Compositions and their use in methods for treating intestinal inflammation
|
TW202400608A
(zh)
|
2022-04-07 |
2024-01-01 |
美商努法倫特公司 |
雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
|
WO2023196910A1
(en)
|
2022-04-07 |
2023-10-12 |
Nuvalent, Inc |
Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
|
WO2023212721A1
(en)
|
2022-04-29 |
2023-11-02 |
Elektrofi, Inc. |
Injectable suspensions
|
WO2023223015A1
(en)
|
2022-05-16 |
2023-11-23 |
Revolo Biotherapeutics Limited |
Methods and compositions for preventing or treating food allergies
|
WO2023250157A1
(en)
|
2022-06-24 |
2023-12-28 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
WO2024013209A1
(en)
|
2022-07-13 |
2024-01-18 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|
WO2024036097A1
(en)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether compounds and isotopologues thereof
|
WO2024036098A1
(en)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether compounds
|
WO2024073334A1
(en)
|
2022-09-26 |
2024-04-04 |
Rose Research Center, Llc |
Combination for use in a method of preventing weight gain
|